Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights
Company reported net ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) sales of $3.8 million in Q2 representing 73% growth over Q1 Strong progress on the ZILRETTA commercial launch: 60% of target accounts have either purchased, or received samples of, ZILRETTA; more than
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to six new employees for an aggregate of 14,800 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML
Toggle Summary Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018
BURLINGTON, Mass. , July 30, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, August 7, 2018 . Flexion’s management will host a conference call at
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , July 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to nine new employees for an aggregate of 30,700 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row
BURLINGTON, Mass. , June 21, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named as one of the Boston Business Journal’s “Best Places to Work” for the second year in a row. Flexion was ranked among the top 15 companies in the medium business
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , June 01, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
View HTML
Toggle Summary Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
Company booked net ZILRETTA ® sales of $2.2 million in Q1 Positive developments in Medicare reimbursement with CMS issuing Q code for ZILRETTA (effective 7/1/18) and recommending dedicated J code (effective 1/1/19) Pivotal Phase 3 trial results published in the Journal of Bone and Joint Surgery
View HTML
Toggle Summary Flexion Therapeutics Names David Arkowitz as Chief Financial Officer
BURLINGTON, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that David Arkowitz has been named Chief Financial Officer (CFO). Mr. Arkowitz brings more than 25 years of finance and operations leadership experience in the life sciences and
View HTML
Toggle Summary Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS
BURLINGTON, Mass., May 04, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the Centers for Medicare and Medicaid Services (CMS) has included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) on its list of products that have been recommended
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to seven new employees for an aggregate of 38,300 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
View HTML